Who can use Vonjo(Pacritinib)?

VONJO is approved under accelerated approval for treating specific types of myelofibrosis in adults with low platelet counts.

Who can use Vonjo(Pacritinib)?

VONJO is indicated for the treatment of intermediate or high-risk primary or secondary myelofibrosis (post-polycythemia vera or post-essential thrombocythemia) in adult patients who have a platelet count below 50 × 10⁹/L. This approval was granted based on the drug's demonstrated ability to achieve spleen volume reduction. The continuation of this approval may depend on further verification of clinical benefit in subsequent confirmatory trials.